Peptide Center / Safety & Pharmacy Check
Verify Before You InjectPeptide safety & pharmacy verification
A practical checklist for patients trying to distinguish a legitimate prescription and regulated pharmacy from a counterfeit, misbranded, contaminated or research-only product.
New numbers, stronger consumer warnings
FDA’s current GLP-1 safety page includes reporting data through May 31, 2026 and new telehealth, fraud and supply-chain details.
Compounded semaglutide
FDA had received 990 adverse-event reports associated with compounded semaglutide. Reports do not by themselves prove causation, and FDA says underreporting is likely because many 503A pharmacies are not federally required to report.
Compounded tirzepatide
FDA had received more than 730 adverse-event reports associated with compounded tirzepatide. Reported concerns include dosing beyond approved labeling and fraudulent products bearing false pharmacy information.
Retatrutide & cagrilintide
FDA states that these investigational substances cannot be used in compounding under federal law and have not been found safe and effective for any condition.
FDA advises patients to avoid companies that skip licensed-clinician screening, claim compounded drugs are the same as approved products, use a pharmacy name that cannot be verified, or ship refrigerated injections warm or inadequately cooled. Do not use an injectable GLP-1 product that arrives warm when its labeling requires refrigeration.
With an unknown-source vial, the name on the label may not match the contents. Sterility, concentration, storage and contaminants may be unknown. Harm can include abscess, sepsis, anaphylaxis, neurologic injury, organ damage, severe dosing events, hospitalization, permanent disability or death.
Do not rely on a website badge
Named prescriber
You should know the clinician’s full name, license type and state. The prescription should follow an actual evaluation—not a checkout quiz designed only to collect payment.
Patient-specific prescription
For ordinary 503A compounding, a valid patient-specific prescription is central. A seller shipping “research” vials directly without a lawful prescription is a major red flag.
State pharmacy license
Verify the exact legal pharmacy name and license with the board of pharmacy in the pharmacy’s home state and, when required, your state.
503B claim verification
If a facility claims 503B status, confirm it on FDA’s current registered outsourcing-facility list. Registration does not mean each compounded drug is FDA-approved.
Inspection and recall history
Review FDA inspection, Form 483, warning-letter and recall records. A registration badge without compliance history is incomplete information.
Traceable medication label
Look for patient name, prescriber, pharmacy, active ingredient and strength, directions, lot or batch information, beyond-use date, storage and pharmacy contact details.
503A and 503B are not the same
| Question | 503A traditional compounding | 503B outsourcing facility |
|---|---|---|
| Primary oversight | State boards of pharmacy, with applicable federal requirements and FDA oversight/enforcement. | FDA registration and oversight plus state requirements. |
| Prescription model | Generally patient-specific prescriptions and limited anticipatory compounding under statutory conditions. | May compound for patient-specific prescriptions or certain office-stock orders under 503B conditions. |
| Manufacturing standard | Must meet applicable pharmacy-compounding standards; generally exempt from CGMP when all 503A conditions are met. | Subject to current good manufacturing practice (CGMP) requirements. |
| FDA-approved product? | No. A compounded drug is not FDA-approved. | No. FDA registration of the facility does not approve each compounded product. |
| Where to verify | State board license plus FDA inspection/enforcement records when available. | FDA registered-outsourcing-facility list, inspection/enforcement records and state license. |
“503A certified” is imprecise marketing language. Section 503A describes statutory conditions; it is not an FDA product-approval seal. Likewise, 503B registration does not guarantee that a facility has no observations or recalls.
What LegitScript can—and cannot—tell you
LegitScript is a private third-party certification and monitoring company used by some advertising, payment and platform partners. Its certification may be an additional signal that a business passed specified checks.
It is not an FDA approval, state pharmacy license, DEA registration, prescription, sterility test or guarantee that a particular compounded medication is safe and lawful. The legal and clinical checks still matter.
Verify the clinician → verify the prescription → verify the pharmacy license → verify any 503B claim → review compliance history → inspect the actual medication label and cold-chain delivery.
Additional quality questions
- Who manufactured the active pharmaceutical ingredient?
- Is the API appropriate for lawful compounding under current federal policy?
- Was the sterile batch tested for potency, sterility and endotoxin where applicable?
- Can the pharmacy identify the lot and provide a certificate of analysis to the prescriber when appropriate?
- Was the medication shipped within its required temperature range?
- Who handles adverse-event reports, temperature excursions and recalls?
Stop before paying when you see these red flags
Seller red flags
- No prescription required or “doctor approval guaranteed”
- Direct sale of injectable vials labeled “research use only” with human dosing instructions
- Crypto, wire transfer, peer-to-peer payment or pressure to buy immediately
- No legal pharmacy name, physical address or verifiable pharmacist
- Claims of “FDA-certified,” “FDA-grade” or “same as the brand” without an approved application
- Before-and-after claims that promise cure, permanent fat loss or no side effects
- Prices far below the legitimate supply chain with no credible explanation
Package red flags
- Misspellings, altered logos or inconsistent concentrations
- No patient name, prescription number, lot, beyond-use date or storage directions
- Broken seal, cloudiness, particles, unexpected color or damaged container
- Warm delivery when refrigeration is required
- Loose syringes or unlabeled vials
- QR code or certificate that links only to the seller’s own unverifiable document
- Medication name does not match the prescription or invoice
Four separate risk layers can stack together
| Risk layer | What can go wrong | Possible consequence |
|---|---|---|
| Identity | Wrong peptide, no active ingredient, undeclared drug or substituted salt/form. | Treatment failure, unexpected pharmacology, poisoning or delayed diagnosis. |
| Potency | Too much, too little, uneven concentration or dosing-unit confusion. | Severe adverse effects, hypoglycemia, dehydration, cardiovascular events or no benefit. |
| Sterility & impurities | Bacteria, fungi, endotoxin, residual solvents, aggregates or peptide-related impurities. | Abscess, sepsis, immune reaction, anaphylaxis or organ injury. |
| Storage & handling | Temperature excursion, degradation, repeated puncture or poor injection hygiene. | Reduced potency, altered product, contamination and infection. |
If a product seems wrong
Do not inject it
Quarantine the product, preserve the box, label, receipt and shipping materials, and contact the prescriber and dispensing pharmacy.
Seek urgent care for symptoms
Emergency symptoms such as trouble breathing, facial swelling, chest pain, fainting, confusion, severe abdominal pain or signs of serious infection need immediate medical evaluation.
Report concerns
Adverse events and product-quality problems can be reported to FDA MedWatch. Suspected illegal online sales can also be reported to FDA.
FDA MedWatchA vial is only as trustworthy
as its entire chain.
Start with a qualified clinician, a valid prescription and a pharmacy you can independently verify.